Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Коррекция дислипидемий при сопутствующей артериальной гипертонии с позиций обновленной парадигмы сердечно-сосудистого риска
Коррекция дислипидемий при сопутствующей артериальной гипертонии с позиций обновленной парадигмы сердечно-сосудистого риска
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Обзор посвящен особенностям комбинированной терапии дислипидемии и артериальной гипертонии с учетом новой оценки уровней сердечно-сосудистого риска, изложенной в европейских и российских рекомендациях 2011–2012 гг. Рассматриваются современные представления о синергетических взаимоотношениях между дислипидемией и артериальной гипертензией. Приводятся данные клинических исследований, посвященных изучению эффективности комбинированного применения амлодипина и аторвастатина у пациентов с дислипидемией и артериальной гипертонией. Обсуждаются результаты использования фиксированных комбинаций этих препаратов с целью улучшения приверженности пациентов лечению.
Ключевые слова: дислипидемия, артериальная гипертония, комбинированная терапия, аторвастатин, амлодипин, приверженность терапии.
The data of clinical trials of the efficiency of co-administration of amlodipine and atorvastatin in patients with dyslipidemia and hypertension are given. The results of using the fixed-dose combinations of these drugs to improve patient compliance with treatment are discussed.
Key words: dyslipidemia, hypertension, combination therapy, atorvastatin, amlodipine, therapy compliance.
Ключевые слова: дислипидемия, артериальная гипертония, комбинированная терапия, аторвастатин, амлодипин, приверженность терапии.
________________________________________________
The data of clinical trials of the efficiency of co-administration of amlodipine and atorvastatin in patients with dyslipidemia and hypertension are given. The results of using the fixed-dose combinations of these drugs to improve patient compliance with treatment are discussed.
Key words: dyslipidemia, hypertension, combination therapy, atorvastatin, amlodipine, therapy compliance.
Полный текст
Список литературы
1. Emberson J, Whincup P, Morris R, Walker M et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004; 25: 484–91.
2. Catapano AL, Reiner Z, De Backer G et al. European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217: 3–46.
3. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. V пересмотр. Атеросклероз и дислипидемии. 2012; 4: 5–52.
4. Folsom AR. Classical and novel biomarkers for cardiovascular risk prediction in the United States. J Epidemiol 2013; 23: 158–62.
5. Kannel WB, Dauber TR, Friedman GD et al. Risk factors in coronary heart disease. An evaluation of several lipids as predictors of coronary heart disease; the Framingem study. Ann Intern Med 1964; 61: 88–9.
6. Borghi C, Veronesi M, Prandin MG et al. Statins and blood pressure regulation. Curr Hypertens Rep 2001; 3: 281–8.
7. Trottier DJ, Kochar MS. Hypertension and high cholesterol: a dangerous synergy. Am J Nurs 1992; 92: 40–3.
8. Borghi C, Prandin MG, Costa FV et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000; 35: 549–55.
9. Stancu CS, Toma L, Sima AV. Dual role of lipoproteins in endothelial cell dysfunction in atherosclerosis. Cell Tissue Res 2012; 349: 433–46.
10. Judkins CP, Diep H, Broughton BR et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice. Am J Physiol Heart Circ Physiol 2010; 298: H24–32.
11. Koniari I, Mavrilas D, Papadaki H et al. Structural and biochemical alterations in rabbit thoracic aorta are associated with the progression of atherosclerosis. Lipids in Health and Disease 2011; 10: 125–34.
12. de Korte CL, Pasterkamp G, van der Steen AF et al. Characterization of plaque components with intravascular ultrasound elastography in human femoral and coronary arteries in vitro. Circulation 2000; 102: 617–23.
13. Aggoun Ya, Bonnet D, Sidi D et al. Arterial mechanical changes in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 2070–5.
14. Laurent S, Boutouyrie P. Arterial stiffness: a new surrogate end point for cardiovascular disease? J Nephrol 2007; 20 (Suppl. 12): S45–50.
15. Sachidanandam K, Hutchinson JR, Elgebaly MM et al. Differential effects of diet-induced dyslipidemia and hyperglycemia on mesenteric resistance artery structure and function in type 2 diabetes. J Pharmacol Exp Ther 2009; 328: 123–30.
16. Igase M, Kohara K, Tabara Y et al. Low-dose rosuvastatin improves the functional and morphological markers of atherosclerosis in asymptomatic postmenopausal women with dyslipidemia. Menopause 2012; 19: 1294–9.
17. Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 2008; 51: 527–39.
18. Stokes KY, Granger DN. The microcirculation: a motor for the systemic inflammatory response and large vessel disease induced by hypercholesterolaemia? J Physiol 2005; 562 (Pt 3): 647–53.
19. Meyer G, MervalR, Tedgui A. Effects of pressure-induced stretch and convection on low-density lipoprotein and albumin uptake in the rabbit aortic wall. Circulation Res 1996; 79: 532–40.
20. Wu CH, Chi GC, Jerng JS et al. Transendothelial macromolecular transport in the aorta of spontaneously hypertensive rats. Hypertension 1990; 16: 154–61.
21. Sun N, Wood NB, Hughes AD et al. Effects of transmural pressure and shear stress on LDL accumulation in the arterial wall: a numerical study using a multilayered model. Am J Physiol Heart Circ Phisiol 2007; 292: H3148–57.
22. Sever P, Dahlöf B, Poulter N et al. ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27: 2982–8.
23. Blank R, LaSalle J, Reeves R, Maroni J et al. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). J Clin Hypertens (Greenwich) 2005; 7: 264–73.
24. Erdine S, Ro YM, Tse HF et al. Gemini-AALA Investigators. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). J Hum Hypertens 2009; 23: 196–10.
25. Messerli FH, Bakris GL, Ferrera D et al. AVALON Investigators. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich) 2006; 8: 571–81.
26. Cohn JN, Wilson DJ, Neutel J et al. Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am J Hypertens 2009; 22: 137–44.
27. Preston RA, Harvey P, Herfert O et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. J Clin Pharmacol 2007; 47: 1555–69.
28. Hobbs FD, Gensini G, Mancini GB et al. JEWEL Study Group. International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. Eur J Cardiovasc Prev Rehabil 2009; 16: 472–80.
29. Hobbs FD, Gensini G, Mancini GB et al. JEWEL Study Group. Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). Int J Cardiol 2006; 110: 242–50.
30. Hradec J, Zamorano J, Sutradhar S. Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial. Curr Med Res Opin 2013; 29: 589–9.
31. Zamorano J, Erdine S, Lopez AP et al. CRUCIAL Investigators. Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study. Postgrad Med 2010; 122: 7–15.
32. Abdel-Zaher AO, Elkoussi AE, Abudahab LH et al. Simvastatin enhances the antihypertensive effect of ramipril in hypertensive hypercholesterolemic animals and patients. Possible role of nitric oxide, oxidative stress, and high sensitivity C-reactive protein. Fundam Clin Pharmacol 2012; 26: 701–10.
33. Rajagopalan S, Zannad F, Radauceanu A et al. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am J Cardiol 2007; 100: 222–6.
34. Koh KK, Quon MJ, Han SH et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687–92.
35. Watanabe H, Kosuge K, Nishio S et al. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci 2004; 76: 281–92.
36. Weiand D, Thoulass J, Smith WC. Assessing and improving adherence with multidrug therapy. Lepr Rev 2012; 83: 282–91.
37. Mahler C, Hermann K, Horne R, et al. Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. J Eval Clin Pract 2010; 16: 574–79.
38. Erdine S, Arslan E. Monitoring treatment adherence in hypertension. Curr Hypertens Rep 2013; 15: 269–72.
39. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep 2013; 15: 291.
40. Maddox TM, Ho PM. Medication adherence and the patient with coronary artery disease: challenges for the practitioner. Curr Opin Cardiol 2009; 24: 468–72.
41. Stang D, Kriston L, von Wolff A et al. Reducing cardiovascular medication complexity in a German university hospital: effects of a structured pharmaceutical management intervention on adherence. JMCP 2013; 19: 396–407.
42. Wilson SA, Sanford A. Amlodipin/Atorvastatin (Caduet) for preventing heart disease. Am Fam Physician 2006; 15: 1067–68.
43. Neutel JM, Bestermann WH, Dyess EM et al. The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich) 2009; 11: 22–30.
2. Catapano AL, Reiner Z, De Backer G et al. European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217: 3–46.
3. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. V пересмотр. Атеросклероз и дислипидемии. 2012; 4: 5–52.
4. Folsom AR. Classical and novel biomarkers for cardiovascular risk prediction in the United States. J Epidemiol 2013; 23: 158–62.
5. Kannel WB, Dauber TR, Friedman GD et al. Risk factors in coronary heart disease. An evaluation of several lipids as predictors of coronary heart disease; the Framingem study. Ann Intern Med 1964; 61: 88–9.
6. Borghi C, Veronesi M, Prandin MG et al. Statins and blood pressure regulation. Curr Hypertens Rep 2001; 3: 281–8.
7. Trottier DJ, Kochar MS. Hypertension and high cholesterol: a dangerous synergy. Am J Nurs 1992; 92: 40–3.
8. Borghi C, Prandin MG, Costa FV et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000; 35: 549–55.
9. Stancu CS, Toma L, Sima AV. Dual role of lipoproteins in endothelial cell dysfunction in atherosclerosis. Cell Tissue Res 2012; 349: 433–46.
10. Judkins CP, Diep H, Broughton BR et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice. Am J Physiol Heart Circ Physiol 2010; 298: H24–32.
11. Koniari I, Mavrilas D, Papadaki H et al. Structural and biochemical alterations in rabbit thoracic aorta are associated with the progression of atherosclerosis. Lipids in Health and Disease 2011; 10: 125–34.
12. de Korte CL, Pasterkamp G, van der Steen AF et al. Characterization of plaque components with intravascular ultrasound elastography in human femoral and coronary arteries in vitro. Circulation 2000; 102: 617–23.
13. Aggoun Ya, Bonnet D, Sidi D et al. Arterial mechanical changes in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 2070–5.
14. Laurent S, Boutouyrie P. Arterial stiffness: a new surrogate end point for cardiovascular disease? J Nephrol 2007; 20 (Suppl. 12): S45–50.
15. Sachidanandam K, Hutchinson JR, Elgebaly MM et al. Differential effects of diet-induced dyslipidemia and hyperglycemia on mesenteric resistance artery structure and function in type 2 diabetes. J Pharmacol Exp Ther 2009; 328: 123–30.
16. Igase M, Kohara K, Tabara Y et al. Low-dose rosuvastatin improves the functional and morphological markers of atherosclerosis in asymptomatic postmenopausal women with dyslipidemia. Menopause 2012; 19: 1294–9.
17. Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 2008; 51: 527–39.
18. Stokes KY, Granger DN. The microcirculation: a motor for the systemic inflammatory response and large vessel disease induced by hypercholesterolaemia? J Physiol 2005; 562 (Pt 3): 647–53.
19. Meyer G, MervalR, Tedgui A. Effects of pressure-induced stretch and convection on low-density lipoprotein and albumin uptake in the rabbit aortic wall. Circulation Res 1996; 79: 532–40.
20. Wu CH, Chi GC, Jerng JS et al. Transendothelial macromolecular transport in the aorta of spontaneously hypertensive rats. Hypertension 1990; 16: 154–61.
21. Sun N, Wood NB, Hughes AD et al. Effects of transmural pressure and shear stress on LDL accumulation in the arterial wall: a numerical study using a multilayered model. Am J Physiol Heart Circ Phisiol 2007; 292: H3148–57.
22. Sever P, Dahlöf B, Poulter N et al. ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27: 2982–8.
23. Blank R, LaSalle J, Reeves R, Maroni J et al. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). J Clin Hypertens (Greenwich) 2005; 7: 264–73.
24. Erdine S, Ro YM, Tse HF et al. Gemini-AALA Investigators. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). J Hum Hypertens 2009; 23: 196–10.
25. Messerli FH, Bakris GL, Ferrera D et al. AVALON Investigators. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich) 2006; 8: 571–81.
26. Cohn JN, Wilson DJ, Neutel J et al. Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am J Hypertens 2009; 22: 137–44.
27. Preston RA, Harvey P, Herfert O et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. J Clin Pharmacol 2007; 47: 1555–69.
28. Hobbs FD, Gensini G, Mancini GB et al. JEWEL Study Group. International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. Eur J Cardiovasc Prev Rehabil 2009; 16: 472–80.
29. Hobbs FD, Gensini G, Mancini GB et al. JEWEL Study Group. Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). Int J Cardiol 2006; 110: 242–50.
30. Hradec J, Zamorano J, Sutradhar S. Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial. Curr Med Res Opin 2013; 29: 589–9.
31. Zamorano J, Erdine S, Lopez AP et al. CRUCIAL Investigators. Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study. Postgrad Med 2010; 122: 7–15.
32. Abdel-Zaher AO, Elkoussi AE, Abudahab LH et al. Simvastatin enhances the antihypertensive effect of ramipril in hypertensive hypercholesterolemic animals and patients. Possible role of nitric oxide, oxidative stress, and high sensitivity C-reactive protein. Fundam Clin Pharmacol 2012; 26: 701–10.
33. Rajagopalan S, Zannad F, Radauceanu A et al. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am J Cardiol 2007; 100: 222–6.
34. Koh KK, Quon MJ, Han SH et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687–92.
35. Watanabe H, Kosuge K, Nishio S et al. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci 2004; 76: 281–92.
36. Weiand D, Thoulass J, Smith WC. Assessing and improving adherence with multidrug therapy. Lepr Rev 2012; 83: 282–91.
37. Mahler C, Hermann K, Horne R, et al. Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. J Eval Clin Pract 2010; 16: 574–79.
38. Erdine S, Arslan E. Monitoring treatment adherence in hypertension. Curr Hypertens Rep 2013; 15: 269–72.
39. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep 2013; 15: 291.
40. Maddox TM, Ho PM. Medication adherence and the patient with coronary artery disease: challenges for the practitioner. Curr Opin Cardiol 2009; 24: 468–72.
41. Stang D, Kriston L, von Wolff A et al. Reducing cardiovascular medication complexity in a German university hospital: effects of a structured pharmaceutical management intervention on adherence. JMCP 2013; 19: 396–407.
42. Wilson SA, Sanford A. Amlodipin/Atorvastatin (Caduet) for preventing heart disease. Am Fam Physician 2006; 15: 1067–68.
43. Neutel JM, Bestermann WH, Dyess EM et al. The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich) 2009; 11: 22–30.
Авторы
В.С.Гуревич
Медицинский факультет ФГБОУ ВПО Санкт-Петербургский государственный университет;
Центр атеросклероза и нарушений липидного обмена Клинической больницы №122 им. Л.Г.Соколова ФМБА России, Санкт-Петербург
Медицинский факультет ФГБОУ ВПО Санкт-Петербургский государственный университет;
Центр атеросклероза и нарушений липидного обмена Клинической больницы №122 им. Л.Г.Соколова ФМБА России, Санкт-Петербург
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.